Revisiting the Flight of Icarus: Making Human Organs from PSCs with Large Animal Chimeras  by Rashid, Tamir et al.
Cell Stem Cell
ForumRevisiting the Flight of Icarus:
Making Human Organs from PSCs
with Large Animal ChimerasTamir Rashid,1,3 Toshihiro Kobayashi,2 and Hiromitsu Nakauchi1,4,5,*
1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge CB2 1QN, UK
3Centre for Stem Cells and Regenerative Medicine and Institute for Liver Studies, Kings College London, SE1 9RT, UK
4Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo,
Tokyo 108-0071, Japan
5Japan Science Technology Agency, ERATO, Nakauchi Stem Cell and Organ Regeneration Project, Tokyo 108-8639, Japan
*Correspondence: nakauchi@stanford.edu
http://dx.doi.org/10.1016/j.stem.2014.09.013
While cell therapies hold great potential for treating many conditions, their utility for treating patients that
require whole organ replacement is unclear. To address this challenge, we propose using genetically engi-
neered ‘‘organ niches’’ in large animals to generate human organs from pluripotent stem cells and discuss
the hurdles facing such strategies.Introduction
Induced pluripotent stem cell (iPSC) tech-
nology has provided us with a simple
demonstration that mature somatic cells
can be reprogrammed into PSCs. This
pivotal landmark has in turn afforded
not only a means of obtaining limitless
sources of human cells but also marks
an instrumental advance for the field
of regenerative medicine (Robinton and
Daley, 2012). The approaches employed
thus far to convert iPSCs into clinically
useful end products have almost univer-
sally sought to imitate naturally occurring
biological phenomena with experimen-
tally engineered production systems.
However, numerous difficulties faced by
researchers in producing mature func-
tional cells via this approach indicate
that the complexity of embryonic develop-
ment may not be amenable to such
imitation. To overcome this challenge,
weproposemethods for generating trans-
plantable human organs grown from
PSCsby compensating for criticalmissing
maturation signals with the help of
specially adapted animal embryos. This
strategy employs a principle first alluded
to in Greek mythology with the flight of
Icarus. In this story, to achieve his ambi-
tious goal of flying, Icarus designed
specially adapted bird’s wings to over-
come the natural limitations of the human
body. Icarus thereby ‘‘chimerized’’ his
own body with the key missing compo-
nent borrowed from a different animal.406 Cell Stem Cell 15, October 2, 2014 ª201‘‘Organ Niche’’ and ‘‘Developmental
Compensation:’’ Two Concepts for
In Vivo OrganGeneration fromPSCs
Current stem cell therapy targets include
diseases that could potentially be cured
by transplantation of healthy cells to
compensate for cell-specific loss-of-
function clinical phenotypes. Examples
include transplantation of dopaminergic
neurons for Parkinson’s disease, oligo-
dendrocytes for spinal cord injury, retinal
pigmented epithelial cells for retinal
degenerative diseases, and hepatocytes
for inherited metabolic disorders. While
this approach provides new hope for a
select group of patients, it will not be
able to treat the more significant numbers
of patients requiring whole organ replace-
ment such as those suffering from end-
stage kidney, heart, lung, and liver failure.
These patients need organs, not cells.
Therefore, generation of whole organs
from iPSCs must now become the most
pressing goal for regenerative medicine.
Despite great developments in tissue en-
gineering as represented by 3D printer
technology and decellularized scaffolds,
generation of functional organs in vitro is
currently impossible. The gap between
the number of patients with end-stage
organ failure and the number of available
donor organs is on the other hand rapidly
increasing.
As an alternative approach to gener-
ating organs from stem cells in vitro,
developmental compensation of organ4 Elsevier Inc.niches harnesses an in vivo environ-
ment to achieve these aims and builds
upon the basic biological concepts of
blastocyst complementation and chimera
generation. Blastocyst complementa-
tion was first reported by Chen et al.
when they demonstrated that deficiency
of T and B lymphocyte lineages in
Rag2-deficient (Rag2/) mice could
be complemented by injecting normal
mouse embryonic stem cells (mESCs)
into Rag2/-mouse-derived blastocysts
(Chen et al., 1993). Because Rag2 is an
indispensable enzyme for rearrangement
of immunoglobulin and T cell receptor
genes, the T and B cells generated in
the complemented animals were mESC
derived; there were no host T or B lym-
phocytes. This complementation was
possible because the Rag2/ host, inca-
pable of generating mature T and B cells,
provided a ‘‘niche’’ for ESC-derived T and
B cells and their progenitors. Observers
therefore postulated that blastocysts
derived from a mutant mouse strain in
which the gene necessary to form a
particular organ was deficient could pro-
vide relevant ‘‘organ niches’’ for normal
ESCs or iPSCs to developmentally
compensate postinjection. This hypothe-
sis was verified when our laboratory
induced pancreas formation in pancrea-
togenesis-disabled embryos. The ‘‘organ
niche’’ here was created by knocking out
the host’s master regulator of Pancreas
development (the Pdx1 gene) with donor

















Figure 1. Potential Methodologies for the Interspecies Generation of Human Organs
(A) Generation of human organs using blastocyst complementation of organogenesis-disabled livestock.
(B) Generation of human organs using in utero conceptus complementation of organogenesis-disabled livestock.
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menting’’ this deficiency to generate
a newly formed pancreas composed
entirely of injected cells (though vessels,
nerves, and interstitial cells were
composed of both host and donor cells;
Kobayashi et al., 2010). These comple-
mented embryos survived to adulthood
without abnormalities, indicating that the
PSC-derived pancreas was functional.
We have obtained similar success in
PSC-derived organ generation for kidney
(Usui et al., 2012). Thus, the concepts of
‘‘organ niche’’ and ‘‘developmental
compensation’’ have been repeatedly
validated experimentally both by us and
others (Isotani et al., 2011, Matsunari
et al., 2013, Kobayashi et al., 2014).
From Rodents to Large Animals
In order to directly translate these experi-
mental observations into the clinical goal
of making patient-specific transplantable
organs, embryos lacking the ability to
generate various organs would be
required. Following organ procurement,
however, those embryos would be sacri-
ficed. Clearly from an ethical and social
perspective this strategy is not appro-
priate to apply to human embryos.
However, given the anatomical and phys-
iological similarity that exists between
human and livestock animal organs, we
might alternatively think about deriving
such organ-generating resources from
pigs and sheep. Pigs are particularly
good animals to use for this purposebecause developmental/genetic engi-
neering techniques like somatic cell nu-
clear transfer (SCNT) are readily available.
Figure 1A outlines this approach. If it
works, although produced in the body of
a pig, the organs would consist of cells
derived from the patient’s own iPSCs,
making the subsequent transplantation
essentially autologous.
While apparently simple, there are a
few significant technical challenges that
need to be addressed before this principle
of organ generation in large animals can
be applied further. These challenges
include issues related to interspecies
chimera generation, large-scale produc-
tion of organ-deficient embryos, the
developmental potential of human PSCs,
posttransplantation cell homing, immune
rejection, and safety and ethical issues.
To address the first issue, we started by
trying to break the interspecies boundary
through transplanting rat iPSCs into
the blastocysts of pancreatogenesis-
disabled mice and vice-versa. As hoped,
we were able to obtain chimeric animals,
giving proof, in rodents at least, that inter-
species complementation was possible.
Interestingly, and as an unexpected sec-
ondary observation, chimeric animals
were found to be either mouse-sized or
rat-sized depending on the host blasto-
cyst—indicating that organ size was
determined by the environment and not
by the donor cells. Shortly after our own
report, a secondgroupconfirmed theprin-
ciple of interspecies complementationCell Stem Cell 1through blastocyst injection using rat
ESCs injected into a mouse embryo engi-
neered to lack a thymus (nu/nu). The
chimeric animals’ thymuses were found
to have been derived from the donor rat
cells, therefore confirming that the pro-
cess could be extended to generate
different organs (Isotani et al., 2011). The
second issue of breeding suitable
numbers of host recipients was ad-
dressed by extending our previousmouse
study inwhichwedemonstrated thatHes1
acts as a fate determinant switch between
the biliary and pancreatic system (Suma-
zaki et al., 2004). Based on these data,
we made transgenic mice with Pdx1-
Hes1 constructs to overexpress Hes1 in
every Pdx1-expressing cell. Transgenic
embryos showed an apancreatic pheno-
type as expected. We then generated a
transgenic pig using the same construct
and succeeded in obtaining apancreatic
embryos just as we had observed in the
mouse. We collected large numbers of fi-
broblasts from this porcine embryo and
carried out SCNT using these fibroblasts
as donor nuclei. The cloned embryos ob-
tained had the same apancreatic pheno-
type, indicating that apancreatic embryos
can be obtained as long as we perform
SCNT using these fibroblasts. As in the ro-
dent system, apancreatic pigs survived to
adulthoodwhen theywere complemented
at the blastocyst stage. Some of them
grew to maturity and became fertile. The
complemented apancreatic male pigs
produced sperm that could also be used5, October 2, 2014 ª2014 Elsevier Inc. 407
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in vitro fertilization, a much easier proce-
dure than SCNT (Matsunari et al., 2013).
Consequently, we have certainly
started to answer the technical chal-
lenges that would be posed by moving
from interrodent complementation to
human-pig complementation. Although
the possibility of interspecies chimera for-
mation has been demonstrated, a reason-
able and major outstanding question for
developing this approach with human
organs is whether the method will work
well enough when attempting to cross
the interspecies boundary that exists be-
tween humans and swine/sheep. It is esti-
mated that humans and pigs diverged
94 million years ago, whereas rat and
mouse did so 25 million years ago (Hed-
ges et al., 2006). It was evident from our
initial experiments that even mouse-rat
interspecific chimera generation rates
were much lower than that of allogenic
chimeras, indicating that a xenogeneic
barrier to making chimeras exists. How-
ever, the underlying cause of this barrier,
and whether the height of the barrier is
variable among species and organs, is
currently not known.
Blastocyst Engrafting Human PSCs
Amore practical issue is that according to
current dogma, existing nonrodent PSCs
are epiblast-stage stem cells and would
not be capable of forming chimeras
after undergoing blastocyst injection.
One could imagine that it would therefore
be difficult to recapitulate the chimeric
data obtained in the rodent studies with
human PSCs. However, recent reports
indicate human naive (or inner-cell-
mass-like) PSCs can be derived and
propagated through the use of special-
ized culture conditions and a cocktail of
several chemical inhibitors (reviewed in
Hackett and Surani, 2014, in this issue
of Cell Stem Cell). It shouldn’t be too
long therefore before we can try blasto-
cyst complementation using such naive
human PSCs. In order to prove their
true potency, generation of interspecies
chimeras may be necessary for such
putatively naive PSCs.
Posttransplantation Issues: Organ
Rejection and Viral Transmission
Assuming we can overcome the afore-
mentioned challenges and generate
blastocyst-engrafting PSCs capable of408 Cell Stem Cell 15, October 2, 2014 ª201forming interspecies chimeric embryos
and subsequently organs, these organs
would contain xenogenic host cells inter-
stitially and in vessels and nerves. This
potential infiltration of host cells could
pose a threat for immunological rejection
once the organs are transplanted into
patients. However, since all parenchymal
cells would be derived from patient
iPSCs, the expected immune responses
should be minimal. To further reduce this
potential complication, however, it may
be necessary to replace host endothelial
cells with donor iPSC-derived cells
using complementation of vasculogene-
sis-disabled host embryos. By combining
two or more genetic mutations, therefore,
we may be able to provide suitable niches
that maximize the contribution of iPSC-
donor cells in the generated organ while
concomitantly reducing potential immu-
nological rejection.
Possible reactivation of porcine endog-
enous viruses (PERV) represents another
posttransplantation concern. Although
this has been proposed as a potential
danger for many years, no case has ever
been reported. On top of this, with the
rapid progress of genetic engineering
technologies such as TALENs and
CRISPRs, it seems possible to genetically
manipulate the host animal genome to
generate PERV-free pigs and therefore
eliminate this possibility altogether.
Safety and Ethical Issues
Research that involves the introduction of
human DNA sequence into animals, or the
mixing of human and animal cells or tis-
sues, to create entities referred to as
‘‘animals containing human material’’
(ACHM) is well-established. Martin
Bobrow recently wrote a comprehensive
report into the subject that we would
recommend that those interested review
for a more in-depth appraisal of this fasci-
nating subject (see the Academy of
Medical Sciences Report at http://www.
acmedsci.ac.uk). Indeed, to us, it is clear
from his and other accounts that thou-
sands of different ACHM models have
already been used in biomedical research
but have yet received relatively little
public discussion. Examples include
mice genetically altered to acquire sus-
ceptibility to diseases which do not
normally affect them such as human
immunodeficiency virus (HIV) and hepati-
tis; chimeric mice, engrafted with pieces4 Elsevier Inc.of human tumor, which have for several
decades been an invaluable system in
cancer research; monoclonal antibody
anticancer therapies, which have been
developed using mice with a ‘‘human-
ized’’ immune system; and goats that pro-
duce a human substance used to treat a
blood clotting disorder.
However, we are sensitive to the fact
that research with the potential to present
the following hypothetical scenarios war-
rants particularly thorough consideration
prior to commencement. (1) Extensive
modification of the brain of an animal, by
implantation of human-derived cells,
which might result in altered cognitive
capacity approaching human ‘‘con-
sciousness’’ or ‘‘sentience’’ or ‘‘human-
like’’ behavioral capabilities. (2) Situations
wherein functional human gametes
(eggs or sperm) might develop from
precursor cell types in an animal, and
where fertilization between either human
(or human-derived) gametes and animal
gametes might then occur. (3) Cellular or
genetic modifications that could result
in animals with aspects of a human-like
appearance (skin type, limb, or facial
structure) or characteristics, such as
speech.
Though the new approach of gener-
ating human organs using livestock ani-
mals involves ‘‘chimerization’’ of the
blastocyst, we are confident that the
aforementioned scenarios would never
be realized. From our experimental results
with interspecific chimeras, we have
always seen a barrier that limits such
gross contribution from the donor (in this
case iPSC-derived cells). Although, as
stated above, the reason is not clear, in
the case of mouse-rat interspecific chi-
meras, donor chimerism is on average
20% (based on chimerism of total fetal
fibroblasts at E13.5), which is much
lower than mouse-mouse allogeneic chi-
meras (about 50%). Moreover, we have
observed embryonic lethality among
interspecific chimera with high donor
iPSC contribution. Even if we succeeded
in generating human-mouse chimeras,
the contribution of human iPSC-derived
cells would probably be less than 1%
(yet the pancreas would ideally be entirely
composed of human cells). The presence
of very small numbers of donor human
cells in pig tissue will in our opinion never
make a humanized pig unless the relevant
organ niche is provided.
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and neural contribution with even greater
confidence, however, we are developing
methods of ‘‘targeted organ generation.’’
For example, by conditional expression
of the transcription factor Mixl1, we were
able to induce differentiation of PSC-
derived cells selectively toward the endo-
dermal lineage, thereby reducing the
number of nonendodermal PSC-derived
cells (Kobayashi et al., 2014). Introducing
constructs containing suicide genes un-
der neural- or germ-cell-specific pro-
moters to completely eliminate formation
of human iPSC-derived neural and germ
cells in the host animal also needs to be
explored. In another, more novel
approach, the use of committed progeni-
tors or organ buds instead of PSCs should
be explored. In organ-deficient embryos,
the organ niche is available for comple-
mentation throughout development of
the organ. Therefore, injected progenitor
cells, instead of PSCs, into the embryo
at the right place and at the right time
may allow complementation of the organ
deficiency with little chance of generating
‘‘off target’’ humanized tissues. We have
called this broader strategy ‘‘interspecies
conceptus complementation’’ or ‘‘ICC’’
rather than blastocyst complementation
(Figure 1B).Conclusions
The flight of Icarus ended in tragedy. Not
because the scientific principle was
wrong, but because in flying too close to
the sun, Icarus did not respect the limita-
tions of his new tools—consequently
burning his wings and crashing into the
sea. Although a real challenge, once we
succeed in generating human organs in
livestock animals, we plan to first utilize
these chimeras for toxicology studies
and disease/therapeutic models. In the
meantime, we will continue to evolve
safety measures for developing the strat-
egy into a clinically useful organ genera-
tion system. If it turns out well, this will
potentially open the way for a future sup-
ply of donor organs as curative therapies
for large numbers of patients with end-
stage organ failure.
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